Recurrent Ganglioneuroblastoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Recurrent Ganglioneuroblastoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT07502287

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neu…

China36 participantsStarted 2026-03-02

Treatment: EB-DTNB-NK, Fludarabine

All recent trials (6 shown)

Not Yet RecruitingPhase 1/2

NCT07437963

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen…

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in tre…

Location not specified76 participantsStarted 2026-07-30

Treatment: Bone Marrow Aspiration, Bone Marrow Biopsy

Active — Not RecruitingPhase 1

NCT02311621

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cell…

United States65 participantsStarted 2014-11-25

Treatment: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)

Recurrent Ganglioneuroblastoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

All recent trials (6 shown)

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen…

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

All recent trials (6 shown)

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen…

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children…

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory…